Pluristem Therapeutics Inc., a developer of placenta-based cell therapy products, has been issued patent #9,096,827 titled “Adherent Cells From Placenta Tissue and Use Thereof in Therapy” from the U.S. Patent and Trademark Office. The patent protects specific methods of culturing placental adherent stromal cells, and use of these cells for the treatment of a wide variety of diseases. Indications covered by the patent include a wide range of ischemic conditions such as heart disease, stroke, p...